GLP-1 drugs are quietly becoming one of the biggest disruptors in employee benefits right now and employers are scrambling to figure out what to do.
What are GLP-1s?
Medications like Ozempic, Wegovy, and Mounjaro were originally for diabetes, but are now widely used for weight loss.
- These drugs can run $1,000+ per month per employee
- When even a small % of employees use them, it blows up employer healthcare budgets
This is quickly becoming one of the largest new line items in group health plans.
Employers are split on coverage
There’s no clear playbook, so companies are doing very different things:
- Covering only for diabetes (not weight loss)
- Requiring prior authorization or BMI thresholds
- Offering access through telehealth + coaching programs
- Or cutting coverage altogether
On paper, GLP-1s could reduce obesity-related conditions, lower long-term healthcare costs, and improve productivity and absenteeism. But in reality, employees often need to stay on them long-term, savings may take years to show up, and many employers aren’t convinced (yet).
What smart employers are doing right now
The most strategic companies aren’t just saying yes or no—they’re:
- Pairing GLP-1 access with lifestyle + behavior coaching
- Adding cost-sharing models to control spend
- Tracking outcomes (weight loss, claims reduction, productivity)
- Communicating clearly to avoid employee backlash
The bottom line
GLP-1s are exposing a tension that’s been building for years:
👉 Employees want access to cutting-edge care
👉 Employers need to control rising costs
How companies handle this will say a lot about their benefits philosophy and their retention strategy
